Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Regen BioPharma (RGBP) Interest & Investment Income (2016 - 2018)

Regen BioPharma (RGBP) has disclosed Interest & Investment Income for 5 consecutive years, with $1302.0 as the latest value for Q4 2018.

  • On a quarterly basis, Interest & Investment Income fell 77.01% to $1302.0 in Q4 2018 year-over-year; TTM through Sep 2019 was $1302.0, a 87.28% decrease, with the full-year FY2022 number at $455.0, changed N/A from a year prior.
  • Interest & Investment Income was $1302.0 for Q4 2018 at Regen BioPharma, up from $113.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $5663.0 in Q4 2017 to a low of $14.0 in Q2 2014.
  • A 5-year average of $840.63 and a median of $300.0 in 2015 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: skyrocketed 2021.43% in 2015, then crashed 90.78% in 2018.
  • Regen BioPharma's Interest & Investment Income stood at $260.0 in 2014, then rose by 15.38% to $300.0 in 2015, then changed by 0.0% to $300.0 in 2016, then skyrocketed by 1787.67% to $5663.0 in 2017, then plummeted by 77.01% to $1302.0 in 2018.
  • Per Business Quant, the three most recent readings for RGBP's Interest & Investment Income are $1302.0 (Q4 2018), $113.0 (Q3 2018), and $577.0 (Q2 2018).